Table: Astellas -Q1 group results (IFRS)

Astellas Pharma

30/07/2025 07:31

Jul 30 (Reuters)- 
              Astellas Pharma Inc. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   3 months ended      3 months ended       Year to 
                  Jun 30, 2025        Jun 30, 2024     Mar 31, 2026 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              505.79              473.12          1.93 trln  
                   (+6.9 pct)          (+26.2 pct)      (+0.9 pct)  
  Operating           94.65               50.66           160.00    
                   (+86.8 pct)         (+10.6 pct)     (+289.9 pct) 
  Pretax              90.42               50.50           150.00    
                   (+79.1 pct)         (+7.8 pct)      (+380.2 pct) 
  Net                 68.42               37.60           130.00    
                   (+82.0 pct)         (+13.5 pct)     (+156.2 pct) 
  EPS Basic         38.22 yen           21.00 yen        72.61 yen  
  EPS Diluted       38.11 yen           20.94 yen                   
  Ann Div                               74.00 yen        78.00 yen  
  -Q2 Div                               37.00 yen        39.00 yen  
  -Q4 Div                               37.00 yen        39.00 yen  
 
  NOTE - Astellas Pharma Inc.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4503.T